Effect of low-dose oral triphasic contraceptives on blood viscosity, coagulation and lipid metabolism.
The purpose of the study was to determine the relationship between hemorheological profile, i.e. blood viscosity, and other risk factors for cardiovascular and thrombotic diseases in women taking oral contraceptives and if blood viscosity may be considered a marker of cardiovascular risk in OC users. Plasma levels of coagulation parameters, serum lipids, blood viscosity and RBC deformability were determined in a group of 10 women taking OC vs. 10 controls. The blood parameters were evaluated before OC use and thereafter at 3 and 6 months. A significant change in the partial thromboplastin time, fibrinogen, HDL and apolipoprotein A-I was observed, while the other parameters remained unchanged. Plasma viscosity was significantly increased during OC treatment; whole blood viscosity and RBC deformability remained unchanged. However, although some parameters were significantly modified during OC treatment, all alterations remained within the normal range of laboratory values. The data confirm that low-dose triphasic OC therapy does not affect significantly the coagulation system, serum lipid metabolism and blood viscosity. Plasma viscosity measurement may be considered as a marker for monitoring women using OC because it is apparently the most sensitive parameter.
Coata
G
G
Institute of Gynecology and Obstetrics, University of Perugia, Italy.
Ventura
F
F
Lombardini
R
R
Ciuffetti
G
G
Cosmi
E V
EV
Di Renzo
G C
GC
D000293:Adolescent; D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects*; D001809:Blood Viscosity / Q000187:drug effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000009:adverse effects*; D004907:Erythrocyte Deformability; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D009652:Norpregnenes / Q000008:administration & dosage / Q000009:adverse effects; D012044:Regression Analysis; D012307:Risk Factors
D003277:Contraceptives, Oral, Combined; D008055:Lipids; D009652:Norpregnenes; C033273:Gestodene; D004997:Ethinyl Estradiol